S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages
Aging · 2024
DOI: 10.18632/aging.205949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Qiankun Ji und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Zhoukou Central Hospital, Zhoukou, Henan 466000, P.R. China. Hauptthemen laut MEDLINE: Glioblastoma, Calgranulin B, Cell Movement, Macrophages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Zhoukou Central Hospital, Zhoukou, Henan 466000, P.R. China.
Zitieren
APA
Ji, Q., Li, Z., Guo, Y., & Zhang, X. (2024). S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages. Aging. https://doi.org/10.18632/aging.205949
Vancouver
Ji Q, Li Z, Guo Y, Zhang X. S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages. Aging. 2024. doi:10.18632/aging.205949
BibTeX
@article{Ji2024,
author = {Ji, Qiankun and Li, Zibo and Guo, Yazhou and Zhang, Xiaoyang},
title = {S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205949}
}
EUVIMED